Enrollment underway in phase 2 trial of nasal spray for neurotrophic keratopathy

Oyster Point Pharma has enrolled the first patient in a phase 2 clinical trial investigating the safety and efficacy of OC-01 nasal spray in patients with neurotrophic keratopathy, according to a press release.The randomized, multicenter, double-masked, placebo-controlled OLYMPIA trial of OC-01 (varenicline) nasal spray is expected to enroll about 100 patients with Mackie’s classification

Read the full article here

Related Articles